Jennifer R Eads, MD

faculty photo
Associate Professor of Clinical Medicine
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
10th Floor South Pavilion
Philadelphia, PA 19104
Education:
BS (Genetics )
University of California, Davis , 1999.
MD
Tufts University School of Medicine , 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

neuroendocrine tumors and esophagogastric cancer

Description of Research Expertise

neuroendocrine tumors and esophagogastric cancer

Selected Publications

Dreyfuss AD, Barsky AR, Plastaras JP, Ben-Josef, Eads JR, Metz JM, Wojcieszynski AP: The efficacy of definitive concurrent proton chemoradiotherapy for esophageal cancer. PTCOG-NA abstract book 2019.

Heckert J, Botterbusch S, Kipnis S, Bennet B, Creamer C, Alderson A, Eads J, Soulen M, Pryma D, Mankoff D, Metz D, Katona B: Initial experience with peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumors (NETs) at a tertiary care United States center. North American Neuroendocrine Tumor Society Abstract book 2019.

Barsky AR, Dreyfuss AD, Plastaras JP, Ben-Josef E, Eads JR, Metz JM, Wojcieszynski AP: The toxicity profile of definitive concurrent proton chemoradiothearpy for esophageal cancer. PTCOG-NA abstract book 2019.

Heckert JM, Eads JR, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Katona BW: Initial experience with peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumor (NET) at a tertiary care United States center. Digestive Disease Week abstract book 2019.

Lee H, Eads JE, Pryma DA: Standardized uptake values on 68Ga-DOTATATE PET/CT predict response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors. Radiological Society of North America (RSNA) 2019 Annual Meeting 2019 Notes: selected for oral presentation.

Eads JR, Krishnamurthi SK, Saltzman JN, Bajor DL, Vinayak S, Barnholtz-Sloan J, Meropol NJ, Markowitz SD, Wang Z: Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors. J Clin Oncol 36, 2018 Notes: poster presentation.

Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB 3rd, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano, T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha, NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G.: NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 16: 693-702, 2018.

Zhao Y, Eads JR, Bajor D, Wang Z: Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials. AACR annual meeting abstract book 2018.

Kim SM, Eads JR: Systemic therapy for the management of neuroendocrine tumor liver metastases. Primary and Metastatic Liver Tumors: Treatment Strategy and Evolving Therapies. Springer, 2017.

Wu H, Opneja A, Sutter C, Eads JR, Tavri S.: Evidence based review of non-surgical management of colorectal cancer liver metastasis and the evolving role of interventional radiology. Digestive Disease Interventions 2017.

back to top
Last updated: 10/31/2019
The Trustees of the University of Pennsylvania